孟鲁司特钠联合沙丁胺醇治疗重度支气管哮喘的临床疗效及安全性分析

Clinical efficacy and safety analysis of Montelukast sodium combined with Salbutamol in treatment of severe bronchial asthma

目的探讨孟鲁司特钠联合沙丁胺醇治疗重度支气管哮喘的临床疗效及其安全性。方法前瞻性选取100例2019年12月—2021年1月商丘市立医院收治的重度支气管哮喘患者作为研究对象,以随机数字表法分为对照组(50例)、试验组(50例)。两组均给予常规对症治疗,对照组在此基础上吸入沙丁胺醇气雾剂,试验组在对照组的基础上口服孟鲁司特钠片,两组均持续治疗1周。比较两组治疗前、治疗1周后的肺功能、血清学指标水平及治疗期间的安全性。结果试验组治疗1周后的总有效率(94.00%)较对照组(70.00%)高,差异有统计学意义(P<0.05)。治疗1周后,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)水平高于治疗前,试验组高于对照组,差异有统计学意义(P<0.05),而呼出气一氧化氮(FeNO)、血清过氧化脂质/过氧化物酶(LPO)、嗜酸粒细胞阳离子蛋白(ECP)水平低于治疗前,试验组低于对照组,差异有统计学意义(P<0.05)。试验组治疗期间的不良反应发生率(8.00%)较对照组(24.00%)低,差异有统计学意义(P<0.05)。结论孟鲁司特钠联合沙丁胺醇可明显降低重度支气管哮喘患者血清LPO、ECP水平,减轻机体炎症反应,并可有效改善患者肺功能,且能降低患者不良反应发生率,提高治疗安全性,疗效显著。

Objective To investigate the clinical efficacy and safety of montelukast sodium combined with salbutamol in the treatment of severe bronchial asthma.Methods Prospectively selected 100 patients with severe bronchial asthma admitted to Shangqiu Municipal Hospital from December 2019 to January 2021 as the research objects,and divided them into the control group(50 cases)and the test group(50 cases)by a random number table.Both groups were given conventional symptomatic treatment.The control group was inhaled with salbutamol aerosol on this basis,and the test group was taken orally with montelukast sodium tablets on the basis of the control group.Both groups continued treatment for 1 week.The pulmonary function,serum index levels and safety during treatment were compared between the two groups before treatment and one week after treatment.Results The total effective rate(94.00%)of the test group after 1 week of treatment was higher than that of the control group(70.00%),and the difference was obviously significant(P<0.05).After 1 week of treatment,the levels of forced expiratory volume(FEV1)and forced vital capacity(FVC)in the first second of the two groups were higher than those before treatment,and the test group was higher than that of the control group,the difference was obviously significant(P<0.05),while the exhaled breath Nitric oxide(FeNO),serum lipid peroxide/peroxidase(LPO),eosinophil cationic protein(ECP)levels were lower than before treatment,and the test group was lower than the control group,the difference was obviously significant(P<0.05).The incidence of adverse reactions during treatment in the test group(8.00%)was lower than that in the control group(24.00%),and the difference was obviously significant(P<0.05).Conclusion Montelukast sodium combined with salbutamol could significantly reduce serum LPO and ECP levels in patients with severe bronchial asthma,reduce inflammation in the body,and can effectively improve the lung function of patients,and could reduce the incidence of adverse reactions in patients,improve the safety of treatment,and had a significant effect.